Originally published here.
Season 1 Episode 4: The role of biotech as the ‘discovery engine’ for pharma - an interview with Felix Lansing, co-founder and CTO of Seamless Therapeutics, with Albert Seymour, CEO of Seamless Therapeutics, on using recombinases to make gene editing more targeted and efficient
Keywords
big pharma, DNA, genes, gene editing, gene therapy, recombinases, CEO, CTO
This episode showcases the role of biotech as the ‘discovery engine’ for pharma in high-risk areas of R&D. It features General Partner Dmitrij (Dima) Hristodorov as he interviews Felix Lansing, co-founder and CTO of Seamless Therapeutics, together with Albert Seymour, CEO of Seamless Therapeutics, on using recombinases to make gene editing more targeted and efficient.
About The Biotech Pulse - a Forbion podcast
Forbion is a leading life sciences venture capital firm founded in the Netherlands, helping companies bridge research and development through our team's expertise in drug development and company building. For over 15 years, we have invested in over 100 companies backing exciting therapies that we believe have the potential to impact the future of medicine. The Biotech Pulse is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.
